Mometasone furoate, the active corticosteroid in Elocon, reduces inflammation in eczema, dermatitis and psoriasis. Elocon tubes are used on inflamed, itchy skin when a stronger topical anti-inflammatory effect is needed. It helps lessen redness, swelling and irritation at the treated site.
Elocon contains mometasone furoate at a concentration of 0.1%. It belongs to the topical corticosteroid class and is applied to affected skin rather than taken by mouth.
A single dose does not suit every person. The amount and duration depend on the strength, body site, diagnosis, age and severity of the flare.
For prescribed use, the usual practical method is:
The face, eyelids, groin, armpits and skin folds absorb topical steroids more readily than thicker areas such as the palms or soles. These sites often need a shorter course or a weaker corticosteroid.
One practical mistake is treating the itch alone while continuing to apply the product for weeks after the inflammation has settled. The absence of itching does not mean that more treatment is needed. A prescriber may advise stopping, reducing frequency or switching to emollient care once the flare is controlled.
Another common problem is applying a very small dot over a broad plaque. That may leave active inflammation untreated and encourage repeated applications. The prescribed amount should be enough to create a thin, even film over the affected skin without leaving thick residue.
Elocon contains mometasone furoate at a concentration of 0.1%. It is a topical corticosteroid applied to affected skin rather than taken by mouth. The medicine is used for inflammatory skin conditions such as eczema, dermatitis and psoriasis flare-ups, and helps reduce redness, itching, scaling, swelling and irritation at the treated site.
Mometasone is a synthetic glucocorticoid corticosteroid. After application, it enters cells in the skin and binds to glucocorticoid receptors. This changes the activity of genes involved in inflammation, reducing the release of cytokines and other inflammatory mediators.
The result is less dilation of small blood vessels, reduced fluid leakage into tissues and lower activity from immune cells in the treated area. Redness, warmth, swelling and itching can then settle. The medicine also produces local vasoconstriction, meaning that small blood vessels narrow temporarily.
The steroid does not work by moisturising the skin. It controls inflammatory activity.
The FDA prescribing information describes mometasone furoate topical products as corticosteroids for reducing inflammatory and itchy skin symptoms [2].
Doctors use topical mometasone for inflammatory conditions such as eczema, dermatitis and psoriasis flare-ups when symptoms include redness, itching, scaling or swelling. The medicine acts locally, although excessive use or application over large areas can increase absorption through the skin [1].
Elocon may reduce the visible and physical symptoms of these conditions, but it does not remove the underlying tendency towards eczema or psoriasis. A flare can return after treatment ends, especially when triggers such as irritants, friction, dry air or untreated infection remain present.
Several practical errors reduce the benefit of topical corticosteroid treatment:
Do not scratch aggressively before application. Scratching creates small breaks that sting when the medicine is applied and can raise the risk of infection.
If the product reaches the eye, rinse with clean water. Repeated exposure around the eyes can raise the risk of eye complications, so application near the eyelids requires special care.
It should not be used on untreated bacterial, fungal or viral skin infections, including cold sores, chickenpox-type eruptions or fungal ring-shaped rashes, unless a clinician has provided a specific treatment plan.
This treatment is not appropriate for:
Greater caution is needed when another corticosteroid is being used at the same time, including steroid tablets, inhalers, injections or other topical steroids. Combining several steroid products can increase total exposure.
Elocon is not suitable for every itchy rash. NOT for you if you have an untreated skin infection, an unexplained rash, or a known allergy to mometasone. Topical corticosteroids can mask infection and allow it to spread.
Extra caution is needed for children, older adults with fragile skin, people with extensive psoriasis, and anyone using the product on the face or skin folds. Infants and very young children should not receive topical mometasone unless a prescriber has expressly selected it.
Tell the prescriber about all treatments applied to the same skin area. Antifungal preparations, antiseptics, dressings and other creams may alter irritation or absorption even when they do not create a classic drug interaction.
Short courses used on suitable areas are generally tolerated well. Local reactions can include burning, stinging, itching, dryness, irritation or redness at the application site. These symptoms may be more noticeable on cracked or freshly scratched skin.
Prolonged use, excessive quantities, frequent application or use under occlusion can cause:
Skin atrophy means thinning of the skin. It may first appear as a shiny, delicate texture or increased visibility of small blood vessels. The risk is higher on the face, genitals, skin folds and other thin-skinned areas.
Systemic absorption is uncommon when topical corticosteroids are used correctly on limited areas. The risk rises when large areas are treated, when treatment continues for a long period, when the skin barrier is damaged or when occlusive dressings are used. Children have a higher surface-area-to-body-weight ratio, so careful supervision is needed.
Stop applying the product to a site that develops a marked rash, facial swelling or severe irritation and obtain prompt medical advice. Rapidly spreading redness, pus, increasing pain or fever can indicate infection rather than an ordinary flare.
Elocon provides anti-inflammatory corticosteroid treatment. Other approaches serve different roles and should not be treated as direct substitutes.
| Treatment category | Main role | Main limitation |
|---|---|---|
| Mometasone topical corticosteroid | Controls moderate inflammatory flares | Requires limits on site, quantity and duration |
| Mild topical corticosteroid | Treats milder inflammation or sensitive areas | May not control thick or severe plaques |
| Emollient | Restores moisture and supports the skin barrier | Does not suppress active immune inflammation |
| Antifungal treatment | Treats fungal infection | Does not treat eczema or psoriasis inflammation |
Emollients used in eczema care may include products based on occlusive, humectant or barrier-supporting ingredients. They can reduce dryness and protect against irritants. They do not replace a corticosteroid when the skin is actively inflamed.
Hydrocortisone is a lower-potency corticosteroid commonly used for mild inflammation. It may be selected for delicate sites or shorter courses. A topical antifungal cream is intended for fungal disease, not for ordinary eczema or plaque psoriasis.
The choice depends on the diagnosis. A rash that resembles eczema may actually be infected, fungal or contact-related. Applying a stronger steroid to the wrong condition can delay appropriate treatment.
In clinical practice, doctors usually assess three features before choosing a topical steroid: the diagnosis, the body site and the severity of inflammation. The same strength may be reasonable for a thick plaque on the elbow but excessive for the eyelid.
Dermatology guidance favours a planned course rather than indefinite daily use. The prescriber may specify when to reduce frequency, stop treatment or continue with emollient care. NICE guidance for atopic eczema also places skin-barrier care and trigger reduction alongside anti-inflammatory treatment [3].
A doctor will normally ask whether the rash is improving, whether it is spreading and whether there are signs of infection. Persistent symptoms despite correct application may indicate the wrong diagnosis, insufficient treatment, an irritant exposure or poor adherence.
One detail patients often miss is that improvement can occur before the skin barrier is fully restored. Stopping all care as soon as redness fades may allow dryness and cracking to return. Continued moisturising can reduce the cycle of flare and scratching.
Skin care habits can influence how often eczema or psoriasis flares, although Elocon acts directly on local inflammation. Avoiding known irritants, using fragrance-free emollients and keeping showers short may reduce additional barrier damage. Exercise is usually compatible with treatment, but sweat, friction and tight clothing can irritate treated areas. NICE guidance on eczema care, reviewed in 2024, supports regular emollient use and avoidance of individual triggers rather than a universal elimination diet .
Older adults may use topical mometasone when a prescriber selects it for the diagnosis and body site. Ageing skin is thinner and more vulnerable to bruising, tearing and steroid-related atrophy, especially on the face, forearms and skin folds. Treatment should therefore use the smallest amount needed for the shortest suitable course. The MHRA’s corticosteroid safety information from 2020 supports careful use of potent topical steroids on vulnerable skin, with review if symptoms persist [4].
Children and teenagers may use topical mometasone when it has been prescribed for an appropriate condition and site. Children can absorb proportionally more topical corticosteroid because of their body size, especially when large areas or dressings are involved. It should not be used on a child’s face, nappy area or skin folds without clear medical instructions. The FDA product information from 2021 for mometasone topical preparations includes age-specific precautions and limits for paediatric use.
Using Elocon alongside another topical corticosteroid, steroid inhaler, steroid injection or steroid tablet can increase total corticosteroid exposure. This does not always make combination treatment inappropriate, but the prescriber should know about every corticosteroid being used. Do not apply a second steroid product to the same area unless the treatment plan specifically includes it. The WHO describes corticosteroids in guidance from 2020 as a broad therapeutic group in which cumulative exposure and route of administration affect safety assessment [5].
Skin thinning is a recognised local adverse effect of topical corticosteroids, with risk influenced by potency, duration, body site, quantity and occlusion. The risk is greater on the face, genitals, skin folds and other thin areas than on thick plaques of the elbows or soles. Fine visible vessels, shiny skin or unusual bruising should prompt a treatment review. The EMA product information from 2023 for topical corticosteroids describes atrophy and related skin changes among possible local reactions.
Elocon does not automatically require complete avoidance of sunlight, but inflamed skin can be more sensitive and should not be deliberately sunburned. Cover treated areas with clothing where practical and use suitable sun protection on exposed skin, keeping sunscreen separate from the medicine unless a clinician advises otherwise. Avoid applying the product immediately before prolonged heat or sun exposure if this increases sweating and irritation. NHS advice from 2024 on topical corticosteroids supports limiting unnecessary exposure to irritants while the skin is healing.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
The itching eased after several applications, and the patch looked less red within the week. I stopped using it on my own once it looked clear and the dryness returned, so I then continued with an emollient as advised.
It only partly settled the cracked skin and was not as helpful as I had hoped. The first applications stung on the open splits, and I was initially using too much because the area felt rough.
The scale reduced and the patch became much less noticeable after several days. I found the treatment useful, but I needed clear instructions because I was tempted to keep applying it after the inflammation had settled.
